CHF 36.12
(0.94%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 9.97 Billion USD | -2.45% |
2022 | 8.6 Billion USD | -2.55% |
2021 | 8.82 Billion USD | 3.26% |
2020 | 8.55 Billion USD | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q1 | 2.53 Billion USD | 19.2% |
2024 Q2 | 2.53 Billion USD | 0.0% |
2023 Q3 | 2.52 Billion USD | 14.43% |
2023 Q1 | 2.25 Billion USD | -2.62% |
2023 FY | 8.39 Billion USD | -2.45% |
2023 Q2 | 2.2 Billion USD | -2.16% |
2023 Q4 | 2.12 Billion USD | -15.89% |
2022 Q1 | 2.15 Billion USD | 0.0% |
2022 FY | 8.6 Billion USD | -2.55% |
2022 Q4 | 2.31 Billion USD | 1.35% |
2022 Q3 | 2.28 Billion USD | 2.39% |
2022 Q2 | 2.23 Billion USD | 3.31% |
2021 FY | 8.82 Billion USD | 3.26% |
2020 FY | 8.55 Billion USD | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Relief Therapeutics Holding AG | 6.03 Million CHF | -165306.929% |
Tecan Group AG | 1.07 Billion CHF | -828.81% |
Santhera Pharmaceuticals Holding AG | 103.41 Million CHF | -9549.564% |
Basilea Pharmaceutica AG | 157.63 Million CHF | -6230.487% |
Bachem Holding AG | 577.31 Million CHF | -1628.516% |
Siegfried Holding AG | 1.27 Billion CHF | -684.825% |
Molecular Partners AG | 7.03 Million CHF | -141687.44% |